31 – 40 of 959
- show: 10
- |
- sort: year (new to old)
- |
- Export
- 2023
- Impact of proton therapy on the DNA damage induction and repair in hematopoietic stem and progenitor cells (2023) SCIENTIFIC REPORTS. 13(1).
- Radiotherapy-specific quality indicators at national level : how to make it happen (2023) RADIOTHERAPY AND ONCOLOGY. 178.
- Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study (2023) CANCER IMMUNOLOGY IMMUNOTHERAPY. 72(2). p.475-491
- Clinical and genomic differences between advanced molecular imaging-detected and conventional imaging-detected metachronous oligometastatic castration-sensitive prostate cancer (2023) EUROPEAN UROLOGY. 84(6). p.531-535
- Performance of MRI for detection of >=T1b disease in local staging of endometrial cancer (2023) 29th European Symposium on Urogenital Radiology (ESUR 2023), Abstracts.
- Experiences of men with prostate cancer participating in a clinical pathway with a supervised group-based exercise program to combat androgen deprivation-induced side effects : a qualitative focus group study (2023) SEMINARS IN ONCOLOGY NURSING. 39(3).
- Cancer treatment data available in European cancer registries : where are we and where are we going? (2023) FRONTIERS IN ONCOLOGY. 13.
- Systematic review and meta-analysis of the association between radiation therapy treatment volume and patient outcomes (2023) INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 117(5). p.1063-1086
- Hypofractionation in breast cancer radiotherapy across World Bank income groups : results of an international survey (2023) JCO GLOBAL ONCOLOGY. 9.
- Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer (2023) ANNALS OF ONCOLOGY. 34(7). p.605-614